Search

Key Takeaways An experimental hormone therapy can extend the lives of women with advanced breast cancer Imlunestrant worked particularly well in combination with the targeted therapy drug Verzenio The combination [...]

INDIANAPOLIS: Eli Lilly and Company has issued the following press release: - Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 EMBER-3 study of imlunestrant, an [...]

INDIANAPOLIS, Nov. 1, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from the Phase 3 trial (EMBER-3) for imlunestrant, an oral selective estrogen receptor degrader [...]

Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of revenue in Q3 2023 from the sale of rights for [...]

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) today announced its financial results for the second quarter of 2024. 'Mounjaro, Zepbound [...]

Revenue in Q2 2024 increased 36%, driven by Mounjaro, Zepbound and Verzenio. When excluding $579.0 million of revenue from the sale of rights for Baqsimi in Q2 2023, revenue in [...]

SEATTLE: Atossa Therapeutics, Inc. has issued the following news release: Atossa Therapeutics, Inc. (Nasdaq: ATOS) ('Atossa' or the 'Company') today announced protocol changes in the previously initiated study to evaluate [...]

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio(r) (abemaciclib; a CDK4/6 inhibitor), Retevmo(r) [...]

Revenue in Q1 2024 increased 26%, driven by Mounjaro, Zepbound, Verzenio and Jardiance. Pipeline progress included positive results from two Phase 3 trials of tirzepatide for obstructive sleep apnea; submission [...]

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) today announced its financial results for the fourth quarter of 2023. '2023 was [...]

Revenue in Q4 2023 increased 28%. New Products[sup.(i)] revenue grew by $2.19 billion to $2.49 billion in Q4 2023, led by Mounjaro and Zepbound. Growth Products[sup.(ii)] revenue increased 9% to [...]

Agreement to provide Verzenio (abemaciclib) free of charge to patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) Lilly joins ongoing effort of [...]

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) announced results from the MONARCH 3 clinical trial, which will be presented in [...]

Results from MONARCH 3 show a numerical improvement in overall survival (OS) of 13.1 months for women with HR+, HER2- metastatic breast cancer treated with Verzenio plus an aromatase inhibitor [...]

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) today announced its financial results for the third quarter of 2023. 'Lilly had [...]

Revenue in Q3 2023 increased 37%, driven by growth from Mounjaro, Verzenio and Jardiance, as well as $1.42 billion from the sale of rights for the olanzapine portfolio (Zyprexa). Excluding [...]

Impact of two years of adjuvant Verzenio treatment is observed well beyond the treatment period, reducing the risk of long-term recurrence by 32% and improving invasive disease-free survival by 7.6% [...]

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio(r) (abemaciclib; a CDK4/6 inhibitor), Retevmo(r) [...]

INDIANAPOLIS, Oct. 6, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio(abemaciclib; a CDK4/6 inhibitor), Retevmo(selpercatinib; a rearranged during transfection [RET] inhibitor), [...]

VANCOUVER, British Columbia: USA News Group has issued the following news release: USA News Group - Earlier this year, the US White House requested over $2.8 billion in funding from [...]

Novartis breast cancer drug Kisqali cut the risk of recurrence by 25% in early-stage breast cancer, positioning the Swiss drugmaker to win new patients and challenge strong rival Eli Lilly. [...]

New analyses from the Phase 3 monarchE trial of two years of Verzenio treatment in node-positive, high risk early breast cancer show similar efficacy across age groups and in patients [...]

Revenue in Q1 2023 decreased 11% driven by a $1.47 billion decline in revenue from COVID-19 antibodies. Excluding COVID-19 antibodies, revenue in Q1 2023 increased 10%, driven by volume growth [...]

High risk patients eligible for Verzenio can now be identified solely based on nodal status, tumor size, and tumor grade, regardless of Ki-67 score Approval supported by four-year data from [...]

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) today announced its financial results for the fourth quarter of 2022. '2023 is [...]

Revenue in Q4 2022 decreased 9%. Excluding COVID-19 antibodies, revenue in Q4 2022 increased 5%, or 10% on a constant currency basis, driven by volume growth of key growth products, [...]

United States: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) today announced that study investigators will present data from its breast cancer [...]

INDIANAPOLIS, Nov. 21, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that study investigators will present data from its breast cancer portfolio and pipeline at the 2022 [...]

Lilly's revenue in Q3 2022 increased 2%, or 7% on a constant currency basis, primarily driven by volume growth of key growth products, partially offset by lower realized prices and [...]

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company ( NYSE: LLY) today announced that data from studies of Verzenio(r) (abemaciclib) and Retevmo(r) (selpercatinib) [...]

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) today announced its financial results for the second quarter of 2022. 'We had [...]

Lilly's revenue in Q2 2022 decreased 4%. On a constant currency basis, revenue decreased 1% as lower realized prices and lower Alimta revenue following the entry of generics more than [...]

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) today announced that data from its oncology portfolio will be presented at the [...]

INDIANAPOLIS, May 26, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from its oncology portfolio will be presented at the 2022 American Society of Clinical [...]

Lilly's revenue growth in Q1 2022 increased 15%, driven by volume growth of 20%. Excluding revenue from COVID-19 antibodies and Alimta, Q1 2022 revenue grew 10%. Outside of revenue from [...]